Hypothesis: an erythropoietin honeymoon phase exists

Kidney International
Steven FishbaneLynda A Szczech

Abstract

TREAT was a recently concluded, and well-powered and designed, study of anemia treatment in chronic kidney disease (CKD). Unlike most previous studies of ESA treatment in nondialysis CKD, TREAT was a placebo-controlled trial. The placebo group in TREAT provides a unique long-term view of a conservative approach to anemia management in nondialysis CKD. The course of mean Hgb levels in the placebo group ran counter to expectations, increasing over time. We discuss possible reasons for this, including a new hypothesis that there may be an erythropoietin 'honeymoon phase' similar to that observed in diabetes mellitus. We propose investigation of this phenomenon as it could lead to less expensive and safer approaches to treatment of CKD anemia.

References

May 9, 1991·The New England Journal of Medicine·A J Erslev
May 1, 1987·Kidney International·A J WalleW Niedermayer
Feb 1, 1984·Kidney International·R J McGonigleJ W Fisher
Mar 27, 2004·Pediatric Diabetes·H Peter ChaseMarian Rewers
Dec 17, 2004·Pediatric Diabetes·Susan Bonner-WeirArun Sharma
Jun 10, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Hanan Aly, Peter Gottlieb
Nov 3, 2009·The New England Journal of Medicine·Marc A PfefferUNKNOWN TREAT Investigators

❮ Previous
Next ❯

Citations

Nov 19, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Lucile MercadalUNKNOWN NephroTest Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

© 2021 Meta ULC. All rights reserved